Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30300699 | 1.00 | MGLL (0.48) | MGLLTAAR1CHRM2MEN1RAB9A | |
| SCHEMBL14063010 | 0.91 | MGLL (0.38) | MGLL | |
| SCHEMBL708540 | 0.91 | MGLL (0.38) | MGLL | |
| SCHEMBL2186411 | 0.87 | SLC6A2 (0.50) | TAAR1MEN1KMT2ATDP1 | |
| SCHEMBL51254 | 0.87 | SLC6A2 (0.50) | TAAR1MEN1KMT2ATDP1 | |
| SCHEMBL873444 | 0.87 | SLC6A2 (0.50) | TAAR1MEN1KMT2ATDP1 | |
| Water SCHEMBL27572757 | 0.85 | SLC6A2 (0.48) | TAAR1MEN1KMT2ATDP1 | |
| Methane SCHEMBL28820455 | 0.85 | SLC6A2 (0.48) | TAAR1MEN1KMT2ATDP1 | |
| SCHEMBL131333 | 0.84 | TDP1 (0.38) | MGLLMEN1KMT2ATDP1 | |
| Ethylene SCHEMBL28205448 | 0.83 | SLC6A2 (0.47) | TAAR1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| EP-1114029-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015614-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | MGLL 3217/4885TAAR1 4531/4885CHRM2 4398/4885 |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | MMP9, MMP1, MMP2 | MGLL 3291/4885TAAR1 4745/4885CHRM2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.